Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care

Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care (December 2019)

Friday, December 6, 2019 in Orlando, Florida
Dinner -- Hyatt Regency Orlando, 6:00 PM ET
Regency Ballroom O-Q, Convention Level


6:00 PM – 6:30 PM Dinner and Registration

6:30 PM – 6:45 PM Welcome and Introduction

6:45 PM – 7:15 PM Driver Mutations, Diagnosis/Contemporary Prognostic Assessments, and Risk-Stratification: Where Are We Now and Where Are We Headed?

7:15 PM – 8:00 PM Tumor Board Discussions: Real-World Cases/Panel Discussion

8:00 PM – 8:45 PM PV and ET in Focus

8:45 PM – 9:10 PM MF in Focus

9:10 PM – 9:30 PM Final Thoughts and Audience Question and Answer Session


Program Chair
Srdan Verstovsek, MD, PhD

Division of Cancer Medicine
Department of Leukemia
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Jean Jacques Kiladjian, MD, PhD

Hôpital Saint Louis
Université de Paris
Paris, France

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Associate Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Raajit K. Rampal, MD, PhD

Assistant Member
Assistant Attending Physician

Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Goal Statement
The goal of this activity is to improve participants’ knowledge of and competence in integrating new agents into the treatment of patients with myeloproliferative neoplasms.

Target Audience
This program is intended for physicians and other healthcare providers who treat and manage patients with myeloproliferative neoplasms.

Learning Objectives

  • Select optimal, individualized treatment for patients with MPNs based on recent advances and evolving best practices to maximize clinical outcomes
  • Integrate emerging agents and regimens for MPNs into routine practice as clinically appropriate
  • Develop an evidence-based treatment plan to improve outcomes in the treatment of MPNs
  • Develop strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion
  • Refer appropriate patients with MPNs to select ongoing clinical trials of novel agents and strategies


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.